 Ryan Fischer
Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 14 | 2023 | 43 | 5.010 |
Why?
| | Liver Diseases | 6 | 2023 | 17 | 2.530 |
Why?
| | Humans | 38 | 2023 | 6599 | 1.280 |
Why?
| | Immunosuppressive Agents | 6 | 2019 | 37 | 1.170 |
Why?
| | Sirolimus | 6 | 2019 | 8 | 1.120 |
Why?
| | Male | 25 | 2022 | 3197 | 1.090 |
Why?
| | Postoperative Complications | 4 | 2020 | 177 | 1.060 |
Why?
| | Child | 23 | 2023 | 3146 | 1.010 |
Why?
| | Fontan Procedure | 2 | 2021 | 19 | 0.950 |
Why?
| | Thrombosis | 1 | 2023 | 15 | 0.930 |
Why?
| | Dendritic Cells | 4 | 2011 | 6 | 0.920 |
Why?
| | Female | 21 | 2022 | 3436 | 0.870 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 9 | 0.780 |
Why?
| | Patient Compliance | 2 | 2020 | 70 | 0.770 |
Why?
| | Cryptosporidiosis | 1 | 2020 | 3 | 0.770 |
Why?
| | Immunocompromised Host | 1 | 2020 | 7 | 0.770 |
Why?
| | Esophageal Neoplasms | 1 | 2020 | 1 | 0.750 |
Why?
| | Scalp | 1 | 2020 | 2 | 0.750 |
Why?
| | Retrospective Studies | 14 | 2023 | 1251 | 0.750 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 2 | 0.750 |
Why?
| | Adenocarcinoma | 1 | 2020 | 8 | 0.750 |
Why?
| | Skin Neoplasms | 1 | 2020 | 8 | 0.740 |
Why?
| | Neoplasms | 1 | 2021 | 119 | 0.710 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2019 | 3 | 0.700 |
Why?
| | Hydrops Fetalis | 1 | 2019 | 4 | 0.690 |
Why?
| | Electronic Health Records | 1 | 2019 | 61 | 0.690 |
Why?
| | Child, Preschool | 13 | 2022 | 1459 | 0.670 |
Why?
| | Infant | 14 | 2023 | 1396 | 0.660 |
Why?
| | Adolescent | 15 | 2022 | 2087 | 0.650 |
Why?
| | Graft Rejection | 3 | 2020 | 31 | 0.640 |
Why?
| | Immune Tolerance | 3 | 2021 | 8 | 0.600 |
Why?
| | Intestines | 2 | 2013 | 26 | 0.590 |
Why?
| | Animals | 6 | 2021 | 563 | 0.550 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2013 | 8 | 0.480 |
Why?
| | Intestinal Atresia | 1 | 2013 | 18 | 0.480 |
Why?
| | Treatment Outcome | 10 | 2021 | 624 | 0.470 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2022 | 14 | 0.460 |
Why?
| | Hypertension, Portal | 2 | 2022 | 7 | 0.430 |
Why?
| | Cholangitis, Sclerosing | 2 | 2023 | 2 | 0.430 |
Why?
| | Isoantigens | 2 | 2011 | 2 | 0.430 |
Why?
| | Myeloid Cells | 1 | 2011 | 1 | 0.410 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2022 | 20 | 0.410 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 10 | 0.410 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 17 | 0.400 |
Why?
| | Hepatolenticular Degeneration | 1 | 2011 | 1 | 0.400 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.390 |
Why?
| | Adult | 7 | 2023 | 1233 | 0.390 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2021 | 3 | 0.380 |
Why?
| | Fatty Liver | 2 | 2013 | 4 | 0.380 |
Why?
| | Short Bowel Syndrome | 3 | 2015 | 4 | 0.370 |
Why?
| | Patient Participation | 2 | 2020 | 21 | 0.360 |
Why?
| | Muscular Dystrophy, Duchenne | 2 | 2019 | 2 | 0.340 |
Why?
| | Prospective Studies | 4 | 2023 | 508 | 0.340 |
Why?
| | Liver Failure | 2 | 2019 | 2 | 0.280 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 9 | 0.270 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2020 | 7 | 0.270 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 5 | 0.270 |
Why?
| | Transition to Adult Care | 2 | 2022 | 18 | 0.260 |
Why?
| | Vancomycin | 2 | 2023 | 17 | 0.260 |
Why?
| | Young Adult | 6 | 2022 | 652 | 0.240 |
Why?
| | Middle Aged | 3 | 2021 | 648 | 0.240 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2023 | 5 | 0.240 |
Why?
| | Aspirin | 1 | 2023 | 5 | 0.240 |
Why?
| | Anticoagulants | 1 | 2023 | 17 | 0.230 |
Why?
| | Hepatic Artery | 1 | 2023 | 7 | 0.230 |
Why?
| | Vascular Diseases | 1 | 2023 | 8 | 0.230 |
Why?
| | Insurance | 1 | 2023 | 1 | 0.230 |
Why?
| | Intestine, Small | 2 | 2013 | 14 | 0.230 |
Why?
| | Cholestasis | 1 | 2022 | 1 | 0.220 |
Why?
| | Alagille Syndrome | 1 | 2022 | 1 | 0.220 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 74 | 0.220 |
Why?
| | Digestive System Diseases | 1 | 2022 | 1 | 0.220 |
Why?
| | Gastroenterology | 1 | 2022 | 10 | 0.220 |
Why?
| | Heart Transplantation | 2 | 2020 | 13 | 0.210 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 14 | 0.210 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 12 | 0.210 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 17 | 0.210 |
Why?
| | Cohort Studies | 2 | 2020 | 264 | 0.210 |
Why?
| | Bile Acids and Salts | 1 | 2021 | 1 | 0.210 |
Why?
| | Adenosine Triphosphatases | 1 | 2021 | 3 | 0.210 |
Why?
| | T-Lymphocytes | 2 | 2013 | 31 | 0.210 |
Why?
| | Tacrolimus | 2 | 2019 | 10 | 0.200 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 238 | 0.190 |
Why?
| | Biliary Tract Diseases | 1 | 2020 | 4 | 0.190 |
Why?
| | Diarrhea | 1 | 2020 | 18 | 0.190 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 24 | 0.190 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2020 | 2 | 0.190 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 15 | 0.190 |
Why?
| | Liver Function Tests | 1 | 2019 | 3 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 11 | 0.180 |
Why?
| | Anticonvulsants | 1 | 2019 | 25 | 0.180 |
Why?
| | Antipsychotic Agents | 1 | 2019 | 14 | 0.180 |
Why?
| | United States | 2 | 2019 | 646 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2011 | 11 | 0.180 |
Why?
| | Incidence | 1 | 2019 | 125 | 0.180 |
Why?
| | Graft Survival | 1 | 2019 | 31 | 0.180 |
Why?
| | Genetic Therapy | 1 | 2019 | 5 | 0.180 |
Why?
| | Ion Channels | 1 | 2019 | 3 | 0.170 |
Why?
| | Ascites | 1 | 2019 | 4 | 0.170 |
Why?
| | Hepatoblastoma | 1 | 2019 | 7 | 0.170 |
Why?
| | Liver Neoplasms | 1 | 2019 | 15 | 0.170 |
Why?
| | Drainage | 1 | 2019 | 34 | 0.170 |
Why?
| | Transplantation Tolerance | 2 | 2010 | 2 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 116 | 0.170 |
Why?
| | Infant, Premature | 1 | 2019 | 81 | 0.160 |
Why?
| | Thrombelastography | 1 | 2018 | 2 | 0.160 |
Why?
| | Resuscitation | 1 | 2018 | 6 | 0.160 |
Why?
| | Blood Transfusion | 1 | 2018 | 13 | 0.160 |
Why?
| | Pregnancy | 1 | 2019 | 203 | 0.160 |
Why?
| | Necrobiotic Xanthogranuloma | 1 | 2018 | 1 | 0.160 |
Why?
| | Pediatric Obesity | 1 | 2020 | 127 | 0.160 |
Why?
| | Dissection | 1 | 2018 | 3 | 0.160 |
Why?
| | Cicatrix | 1 | 2018 | 5 | 0.160 |
Why?
| | Caregivers | 1 | 2018 | 38 | 0.160 |
Why?
| | Skin | 1 | 2018 | 13 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2018 | 29 | 0.160 |
Why?
| | Liver | 2 | 2022 | 119 | 0.160 |
Why?
| | Quality of Life | 1 | 2018 | 131 | 0.150 |
Why?
| | Intestinal Diseases | 2 | 2013 | 4 | 0.150 |
Why?
| | Prognosis | 2 | 2021 | 209 | 0.140 |
Why?
| | Bilirubin | 3 | 2023 | 25 | 0.140 |
Why?
| | Health Resources | 1 | 2015 | 17 | 0.140 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 8 | 0.130 |
Why?
| | Mice | 3 | 2011 | 290 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 181 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2013 | 142 | 0.120 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 11 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2013 | 11 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 28 | 0.120 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 25 | 0.120 |
Why?
| | Parenteral Nutrition, Total | 1 | 2013 | 7 | 0.120 |
Why?
| | Calcineurin | 1 | 2013 | 1 | 0.120 |
Why?
| | Pancreas Transplantation | 1 | 2013 | 2 | 0.120 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2013 | 2 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 5 | 0.120 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2013 | 1 | 0.120 |
Why?
| | Fish Oils | 1 | 2013 | 1 | 0.120 |
Why?
| | Infant, Newborn | 3 | 2023 | 790 | 0.110 |
Why?
| | Apoptosis | 1 | 2012 | 43 | 0.110 |
Why?
| | Portal Vein | 2 | 2023 | 8 | 0.110 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 7 | 0.110 |
Why?
| | Transplantation, Isogeneic | 1 | 2011 | 1 | 0.100 |
Why?
| | Cell Survival | 1 | 2011 | 19 | 0.100 |
Why?
| | Mice, Knockout | 1 | 2011 | 54 | 0.100 |
Why?
| | Body Mass Index | 2 | 2022 | 155 | 0.100 |
Why?
| | Risk Assessment | 2 | 2021 | 130 | 0.100 |
Why?
| | Biopsy | 3 | 2018 | 56 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2021 | 315 | 0.090 |
Why?
| | Antigen Presentation | 1 | 2009 | 1 | 0.090 |
Why?
| | Metformin | 1 | 2009 | 5 | 0.090 |
Why?
| | Chemotaxis | 1 | 2009 | 2 | 0.090 |
Why?
| | Immunotherapy, Adoptive | 1 | 2009 | 6 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2009 | 23 | 0.090 |
Why?
| | Cytokines | 1 | 2009 | 48 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 62 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2009 | 64 | 0.080 |
Why?
| | Signal Transduction | 1 | 2009 | 107 | 0.080 |
Why?
| | Recurrence | 2 | 2019 | 115 | 0.080 |
Why?
| | Obesity | 1 | 2009 | 124 | 0.080 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 1 | 0.080 |
Why?
| | Pediatrics | 2 | 2019 | 170 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 7 | 0.070 |
Why?
| | Steroids | 2 | 2019 | 14 | 0.070 |
Why?
| | Disease Progression | 2 | 2019 | 104 | 0.070 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 3 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 17 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Registries | 1 | 2023 | 85 | 0.060 |
Why?
| | Prevalence | 1 | 2023 | 145 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.060 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 4 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2022 | 5 | 0.060 |
Why?
| | Patient Transfer | 1 | 2022 | 8 | 0.050 |
Why?
| | Vaccination | 1 | 2022 | 68 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 46 | 0.050 |
Why?
| | Societies, Medical | 1 | 2022 | 43 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2022 | 7 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 15 | 0.050 |
Why?
| | Urban Population | 1 | 2022 | 36 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2021 | 1 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2021 | 6 | 0.050 |
Why?
| | Rural Population | 1 | 2022 | 38 | 0.050 |
Why?
| | Survival Analysis | 1 | 2021 | 46 | 0.050 |
Why?
| | Data Mining | 1 | 2021 | 5 | 0.050 |
Why?
| | Data Collection | 1 | 2021 | 32 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2021 | 150 | 0.050 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 3 | 0.050 |
Why?
| | Databases, Factual | 1 | 2021 | 105 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2020 | 16 | 0.050 |
Why?
| | Age Factors | 1 | 2021 | 203 | 0.050 |
Why?
| | Aged | 1 | 2021 | 375 | 0.050 |
Why?
| | Waiting Lists | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2019 | 40 | 0.040 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 16 | 0.040 |
Why?
| | Patient Preference | 1 | 2019 | 6 | 0.040 |
Why?
| | Algorithms | 1 | 2020 | 103 | 0.040 |
Why?
| | Risk Factors | 1 | 2021 | 460 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 34 | 0.040 |
Why?
| | Cisplatin | 1 | 2019 | 8 | 0.040 |
Why?
| | Patient Safety | 1 | 2019 | 20 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 60 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2019 | 69 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 57 | 0.040 |
Why?
| | Kidney | 1 | 2019 | 89 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 111 | 0.040 |
Why?
| | Plasma | 1 | 2018 | 7 | 0.040 |
Why?
| | Back | 1 | 2018 | 1 | 0.040 |
Why?
| | Abdomen | 1 | 2018 | 13 | 0.040 |
Why?
| | Thigh | 1 | 2018 | 5 | 0.040 |
Why?
| | Parents | 1 | 2019 | 149 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2015 | 21 | 0.030 |
Why?
| | Hospital Costs | 1 | 2015 | 27 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 63 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 21 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 202 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 44 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 31 | 0.030 |
Why?
| | Length of Stay | 1 | 2015 | 227 | 0.030 |
Why?
| | Hospitalization | 1 | 2015 | 192 | 0.030 |
Why?
| | Transaminases | 1 | 2013 | 1 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 1 | 0.030 |
Why?
| | Hemolysis | 1 | 2013 | 3 | 0.030 |
Why?
| | Plasmapheresis | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation | 1 | 2013 | 2 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 2 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 3 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2013 | 8 | 0.030 |
Why?
| | Cyclosporine | 1 | 2013 | 6 | 0.030 |
Why?
| | Body Height | 1 | 2013 | 31 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 9 | 0.030 |
Why?
| | Medical Records | 1 | 2013 | 14 | 0.030 |
Why?
| | Penicillins | 1 | 2013 | 8 | 0.030 |
Why?
| | Nebraska | 1 | 2013 | 2 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2013 | 9 | 0.030 |
Why?
| | Intestinal Volvulus | 1 | 2013 | 12 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 9 | 0.030 |
Why?
| | Triglycerides | 1 | 2013 | 20 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2013 | 27 | 0.030 |
Why?
| | Gastroschisis | 1 | 2013 | 21 | 0.030 |
Why?
| | Epithelium | 1 | 2012 | 6 | 0.030 |
Why?
| | Observer Variation | 1 | 2012 | 12 | 0.030 |
Why?
| | Time Factors | 1 | 2013 | 241 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2012 | 197 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2010 | 26 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 73 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 6 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 6 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 14 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 25 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 76 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|